Precision Medicine is the term used to encapsulate treatments tailored to the individual patient on the basis of genetic, biological, phenotypic, or psychosocial factors. It therefore uses individual characteristics to risk-stratify, inform future health status, determine intervention and predict prognosis. This approach has changed the management of several conditions in general medicine, such as cardiology and oncology (National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease, 2011) . The evolution has been much more protracted in psychiatry, given the complexity underpinning the aetiology of mental illnesses and diagnostic boundaries. With new neuroimaging technologies and latest advances in analytical strategies such as network analysis and machine learning, it may now be possible to apply this precision approach to psychiatry, including eating disorders (Bzdok & MeyerLindenberg, 2018; Joyce, Kehagia, Tracy, Proctor, & Shergill, 2017; Loth et al., 2017; Schumann et al., 2014; Silbersweig & Loscalzo, 2017; Vieta, 2015; Zipfel & Schmidt, 2018) .
Precision medicine has the potential to revolutionise psychiatry, offering a range of exciting opportunities for optimising the prevention, diagnosis, and treatment of mental disorders. It is therefore time for us to move away from a "one size fits all" approach whereby we use evidence about the average effect of a treatment to tailored, individual treatment using an in-depth characterisation of the individual (Brockmeyer, Friederich, & Schmidt, 2018; Nazar et al., 2016; Palavras, Hay, Filho, & Claudino, 2017; Peat et al., 2017) . Elements of a clinical signature for disease may include signs, symptoms, outcome trajectory, and biomarkers such as genome (Stein & Smoller, 2018) , connectome (Riva-Posse et al., 2018) , inflammasome ("Big data meets mechanism," 2015) and cognitive/emotional traits (Cotter & Barnett, 2018) . The term "theragnostics" has been used for the process of identifying biomarkers that predict the treatment response to a specific intervention in a specific individual at a specific stage of the illness (Heilig & Leggio, 2016) .
Staging is a concept allied to precision psychiatry with the idea that the clinical signature changes over time and is linked to the duration of untreated illness. In eating disorders, processes such as neuroadaptation, neuroprogression, and social exclusion are thought to contribute to the evolution of the disorder into the severe enduring state (Treasure & Russell, 2011; Treasure, Stein, & Maguire, 2015) . Following from this, it is likely that biomarkers which can predict treatment response to specific therapies in a given individual at a certain point in his/her disease process may change over time.
This personalised approach to treatment fits with what patients with eating disorders request from their clinicians (Cardi, Matteo, Gilbert, & Treasure, 2014; van Furth, van der Meer, & Cowan, 2016) . In this article, (a common is added) we consider how this concept can be applied to eating disorders by referencing what is already known in this and allied fields and consider the implications for treatment.
| EXAMPLES OF PRECISION PSYCHIATRY
In other domains of psychiatry, evidence in support of the relevance of precision psychiatry is accumulating. For example, various risk factors and biomarkers have been identified to explain the varied response to antidepressants observed in people with depression. Poorer response to antidepressants have been associated with childhood trauma (Miller et al., 2015) and anomalies in brain structure such as reduced frontal volume and fractional anisotropy (Korgaonkar et al., 2015) . Markers of generalised inflammation such as C-reactive protein predict the differential response to escitalopram or nortriptyline (Uher et al., 2014) . Moreover, a large synthesis of brain connectivity data has been use to generate subgroups of depression. These novel subtypes were found to be relevant as predictors of the response to neurostimulation procedures (Drysdale et al., 2017) . In addition, the early restoration of normal processing of affective stimuli by antidepressant treatment has been found to predict later clinical improvement (Harmer, Duman, & Cowen, 2017) .
Similarly, a differential response to treatment in addiction, in particular to alcohol misuse, can be explained by various clinical signatures (Heilig et al., 2010; Heilig & Leggio, 2016) . For example, people with a family history of alcohol problems respond to naloxone treatment and this is associated with genetic variation of the μ-opioid receptor gene (Anton et al., 2008; Oroszi et al., 2009; Ray & Hutchison, 2007) . A response to naloxone is associated with a phenotype characterised by high alcohol craving and sweet-liking (Garbutt, Kampov-Polevoy, Kalka-Juhl, & Gallop, 2016) . These findings in conditions which are often comorbid with eating disorders suggests that we need to consider their implications in the treatment for eating disorders, such as risk-stratification.
| RISK STRATIFICATION (PRECISION PSYCHIATRY) IN EATING DISORDERS
Interestingly one of the earliest treatment trials of psychotherapy in eating disorders demonstrated the relevance of stratification of patients based on duration of illness. The trial examined different forms of relapse prevention for anorexia nervosa post-inpatient weight restoration. They compared family therapy and individual therapy at 1-and 5-years post-discharge (Eisler et al., 1997; Russell, Szmukler, Dare, & Eisler, 1987) . Patients with a longer duration of illness (greater than 3 years) responded poorly to both forms of treatment at both follow-ups. Those with a shorter duration of illness (less than 3 years) had a differential, superior response to family therapy compared to individual treatment. The superiority of family therapy over individual therapy to prevent relapse following inpatient treatment has been replicated in adolescents (Godart et al., 2012) . In addition, family therapy was more effective than individual therapy in facilitating full remission at follow up for adolescents with anorexia nervosa (Lock et al., 2010) . Interestingly a recent study using bivariate latent basis growth curve modelling, reported an association between individual trajectory of weight change and eating-related obsessionality (Byrne et al., 2018) . This relation was only observed in individuals with anorexia nervosa who were receiving familybased treatment, and not those who had individual therapy. This raises the possibility that people with high levels of eating-related obsessionality might benefit more from treatment focusing on habit change through procedures such as exposure and response prevention. These findings suggest that in addition to duration of illness, eating disorder obsessionality might also be used as a predictor in determining the best treatment for an individual.
Other potential risk factors for selecting the best treatment for people with anorexia nervosa have been suggested. Recent results from a meta-analysis (n = 126 studies) reported that baseline predictors such as higher BMI, fewer binge/purge behaviours, fewer psychiatric comorbidities, better interpersonal functioning, fewer familial problem, greater motivation to recover, lower depression, and lower shape/weight concern predict better treatment outcome in people with eating disorders (Vall & Wade, 2015) . In addition, impulsivity or traits associated with reward reinforcement, often associated with binging and purging, are obvious candidates. There has also been the suggestion that people with anorexia nervosa who shared traits with autistic spectrum conditions, such as anxiety, interoceptive anomalies, and social difficulties, might benefit from different treatment. However, there is no concrete evidence to support this at present. These are potential "low-hanging" fruits for future exploration in developing precision medicine for people with anorexia nervosa.
| CONCLUSION
Treatment trials of adults with anorexia nervosa include a substantial proportion with a prolonged period of untreated illness. It could be argued that the findings from these studies have led to "therapeutic stagnation." For example, no superiority of a specific psychological approach has been observed for adults with anorexia nervosa (Grenon et al., 2018; Zeeck et al., 2018) . In addition, all produce only moderate sized effects. There are several explanations for this. One is that improvement is caused by nonspecific, therapeutic effects such as the alliance. Another is that all of these treatments contain similar health behaviour change strategies such as planning and monitoring of eating behaviour. It is now necessary to move away from the stance of being agnostic as to aetiology underpinning eating disorders that was adopted when family-based therapy was introduced, to developing treatment that closes the translational gap between the advances made in neuroscience and the clinic. Thus, we may need to tailor treatment and supplement interventions by targeting specific elements of risk and resilience. This would require a deeper phenotyping to examine facets of the core psychopathology including social and interpersonal function, reward reinforcement, anxiety sensitivity, cognitive styles, and other biomarkers. This will require more research examining longitudinal trajectories rather than relying on work which uses the average response.
